3iM
Stockholm, Sweden3iM (3iM Equity Partners) is a Stockholm-based North European equity investor that takes control positions in small consumer-healthcare, FMCG and retail companies with equity values up to EUR 25m, deploying founder capital deal-by-deal through dedicated vehicles rather than a blind-pool fund.
3iM is a Stockholm buyout firm with 1 active company and 1 exit.
Key facts
Recent exits
3iM sold Allderma to Avia Pharma (Impilo) in 2026 after 6 years.
Coverage notes
1 fund tracked, 2 portfolio companies (1 active · 1 realized). Verified weekly from public filings and deal announcements.
Investment team
Senior partners. Hand-checked from public filings and the firm's own site.
Funds & portfolio
Every fund 3iM has raised, with its portfolio companies. Hand-checked from public filings.
3iM Equity PartnersRealizedSmall-Mid Buyout20201 assets1 exitsSmall-Mid Buyout2020 · 6yr–11
Unrealized
1 held| Company | Entry |
|---|---|
| Swedish Fika Consumer · Sweden | 2025 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Allderma Pharma · Sweden | 2020 | 2026 | Trade Sale | Avia Pharma (Impilo) | – |
Frequently asked questions
- What investment strategy does 3iM focus on?
- 3iM focuses on Buyout, Growth strategies in the private equity space.
- How many portfolio companies does 3iM have?
- 3iM has 1 active portfolio company and 1 completed exit and 1 fund tracked on GP Intel.
- Where is 3iM headquartered?
- 3iM is headquartered in Stockholm, Sweden.
- What sectors does 3iM invest in?
- 3iM invests across Healthcare, Consumer.
- What are 3iM's recent exits?
- Recent realized exits by 3iM include: Allderma (2026) to Avia Pharma (Impilo).
Similar firms
Other private equity firms tracked on GP Intel.
